XTX Topco’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-36,518
Closed -$1.86M 4204
2025
Q4
$1.86M Buy
36,518
+29,643
+431% +$1.52M 0.05% 608
2025
Q3
$381K Buy
6,875
+731
+12% +$42.8K 0.02% 1303
2025
Q2
$424K Sell
6,144
-4,018
-40% -$273K 0.02% 1213
2025
Q1
$706K Buy
+10,162
New +$839K 0.04% 773
2024
Q4
Sell
-6,129
Closed -$730K 2735
2024
Q3
$730K Sell
6,129
-18,761
-75% -$2.5M 0.05% 576
2024
Q2
$3.55M Buy
24,890
+20,482
+465% +$2.71M 0.3% 29
2024
Q1
$566K Sell
4,408
-1,483
-25% -$177K 0.08% 419
2023
Q4
$609K Buy
+5,891
New +$583K 0.13% 164
2023
Q3
Sell
-4,552
Closed -$368K 1868
2023
Q2
$368K Buy
+4,552
New +$372K 0.07% 566
2023
Q1
Sell
-14,350
Closed -$971K 1547
2022
Q4
$971K Buy
+14,350
New +$841K 0.21% 95
2022
Q1
Sell
-4,792
Closed -$268K 877
2021
Q4
$268K Sell
4,792
-7,604
-61% -$412K 0.15% 242
2021
Q3
$595K Buy
+12,396
New +$599K 0.2% 139
2021
Q2
Sell
-11,544
Closed -$389K 1008
2021
Q1
$389K Buy
+11,544
New +$411K 0.19% 177

Other funds holding NVO

XTX Topco's NVO Position: Q1 2026 in Review

XTX Topco sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 36,518 shares — an estimated $1.86M sold.

XTX Topco first reported a position in NVO in Q1 2021 and held it in 13 quarters. The position peaked at $3.55M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • XTX Topco reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 36,518 Novo Nordisk shares in Q1 2026, an estimated $1.86M.
  • XTX Topco first reported a position in Novo Nordisk in Q1 2021 and held it in 13 quarters.
  • XTX Topco's Novo Nordisk position peaked at $3.55M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.